CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT04704323
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
Lymphocytic Leukemia, Chronic
SLL
Interventions
DRUG:
CAP-100
Sponsor
Catapult Therapeutics